Vaccine development for leptospirosis: A systematic review

Abstract

Objective: To assess the efficacy of various types of vaccines developed for leptospirosis.

Methods: A comprehensive search was conducted in three databases: PubMed, Scopus, and Cochrane Library. Two authors (YS and MN) selected the articles based on manual screening. The study eligibility criteria are all Leptospira species regardless of any cluster (pathogenic, intermediate and non-pathogenic). This study recorded articles with positive and negative results and showed a comparison among various membrane proteins as vaccine candidates. The studies on the effectiveness of outer membrane protein as vaccine candidates were also included. The articles obtained in the databases were imported into the WPS spreadsheet, and duplicate documents were removed manually.

Results: A total of 24 studies were included in the review, which evaluated various types of leptospirosis vaccines. Multiple vaccines were developed and tested; however, the heterogeneity of Leptospira species pose a challenge. As an effective approach, an epitope based vaccine shows quite a promising result. However, sufficient validation, testing and clinical trials are required.

Conclusions: Developing an effective vaccine for leptospirosis remains a global health priority. While significant progress has been made in recent years, there is a need for further research to optimize vaccine development and to ensure that vaccines are accessible and effective for high-risk populations.

Keywords

Vaccine candidate / Outer membrane protein

References

[1] Azocar-Aedo L. Basic aspects and epidemiological studies on leptospirosis carried out in animals in Chile: A bibliographic review. Trop Med Infect Dis 2023; 8(2): 97. doi: 10.3390/tropicalmed8020097.

[2] Wilkinson DA, Edwards M, Benschop J, Nisa S. Identification of pathogenic Leptospira species and serovars in New Zealand using metabarcoding. PLoS One 2021; 16(9): e0257971.

[3] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol 2010; 140(3-4): 287-296.

[4] Sun A, Liu X, Yan J. Leptospirosis is an invasive infectious and systemic inflammatory disease. Biomed J 2020; 43(1): 24-31.

[5] Lindo J, Brown PD, Vickers I, Brown M, Jackson ST, Lewis-Fuller E. Leptospirosis and malaria as causes of febrile illness during a dengue epidemic in Jamaica. Pathog Glob Health 2013; 107(6): 329-334.

[6] Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol 2015; 387: 65-97.

[7] Rajapakse S. Leptospirosis: Clinical aspects. Clin Med 2022; 22(1): 14-17.

[8] Rahman MT, Sobur MA, Islam MS, Ievy S, Hossain MJ, El Zowalaty ME, et al. Zoonotic diseases: Etiology, impact, and control. Microorganisms 2020; 8(9): 1405.

[9] Fornazari F, Richini-Pereira VB, Joaquim SF, Nachtigall PG, Langoni H. Leptospirosis diagnosis among patients suspected of dengue fever in Brazil. J Venom Anim Toxins Incl Trop Dis 2021; 27: e20200118.

[10] Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2. 0. PLoS Biol 2020; 18(7): e3000411.

[11] Bacelo KL, Hartwig DD, Seixas FK, Schuch R, Moreira ADS, Amaral M, et al. Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis. Biomed Res Int 2014; 2014: 636491.

[12] Monaris D, Sbrogio-Almeida ME, Dib CC, Canhamero TA, Souza GO, Vasconcellos SA, et al. Protective immunity and reduced renal colonization induced by vaccines containing recombinant Leptospira interrogans outer membrane proteins and flagellin adjuvant. Clin Vaccine Immunol 2015; 22(8): 965-973.

[13] Oliveira TL, Grassmann AA, Schuch RA, Pinto Seixas Neto AC, Mendonça M, Hartwig DD, et al. Evaluation of the Leptospira interrogans outer membrane protein OmpL37 as a vaccine candidate. PLoS One 2015; 10(11): e0142821.

[14] Forster KM, Hartwig DD, Oliveira TL, Bacelo KL, Schuch R, Amaral MG, et al. DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis. Memorias Do Instituto Oswaldo Cruz 2015; 110(8): 989-995.

[15] Vijayachari P, Vedhagiri K, Mallilankaraman K, Mathur PP, Sardesai NY, Weiner DB, et al. Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45. Hum Vaccin Immunother 2015; 11(8): 1945-1953.

[16] Lin X, Xiao G, Luo D, Kong L, Chen X, Sun D, et al. Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in Guinea pigs. BMC Microbiol 2016; 16(1): 1-9.

[17] Fernandes LGV, Teixeira AF, Filho AFS, Souza GO, Vasconcellos SA, Heinemann MB, et al. Immune response and protective profile elicited by a multi-epitope chimeric protein derived from Leptospira interrogans. Int J Infect Dis 2017; 57: 61-69.

[18] Conrad NL, Cruz McBride FW, Souza JD, Silveira MM, Félix S, Mendonça KS, et al. LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis. PLoS Negl Trop Dis 2017; 11(3): 1-20.

[19] Evangelista KV, Lourdault K, Matsunaga J, Haake DA. Immunoprotective properties of recombinant LigA and LigB in a hamster model of acute leptospirosis. PLoS One 2017; 12(7): 1-21.

[20] Raja V, Sobana S, Mercy CSA, Cotto B, Bora DP, Natarajaseenivasan K. Heterologous DNA prime-protein boost immunization with RecA and FliD offers cross-clade protection against leptospiral infection. Sci Rep 2018; 8(1): 1-9.

[21] Teixeira AF, Fernandes LGV, Souza Filho A, Souza GO, Vasconcellos SA, Heinemann MB, et al. Evaluation of Lsa46 and Lsa77 leptospiral proteins for their immunoprotective activities in hamster model of leptospirosis. Biomed Res Int 2018; 2018: 17-22.

[22] Larré T, Rizzi C, Eduardo C, Dorneles J, Clair A, Seixas P, et al. LemA and Erp Y-like recombinant proteins from Leptospira interrogans protect hamsters from challenge using AddaVax™ as adjuvant. Vaccine 2018; 36(9): 2574-2580.

[23] Techawiwattanaboon T, Barnier-Quer C, Palaga T, Jacquet A, Collin N, Sangjun N, et al. Reduced renal colonization and enhanced protection by leptospiral factor h binding proteins as a multisubunit vaccine against leptospirosis in hamsters. Vaccines 2019; 7(3): 95.

[24] Costa M, Martins G, Ribeiro B, Correia L. Assessment of the immunogenicity of the leptospiral LipL32, LigAni, and LigBrep recombinant proteins in the sheep model. Comp Immunol Microbiol Infect Dis 2019; 65: 176-180.

[25] Larré T, Rizzi C, Eduardo C, Dorneles J, Clair A, Seixas P, et al. Recombinant BCG strains expressing chimeric proteins derived from Leptospira protect hamsters against leptospirosis. Vaccine 2019; 37(6): 776-782.

[26] Techawiwattanaboon T, Barnier-quer C, Palaga T, Patarakul K. A comparison of intramuscular and subcutaneous administration of LigA subunit vaccine adjuvanted with neutral liposomal formulation containing monophosphoryl Lipid A and QS21. Vaccines 2020; 8(3): 494.

[27] Oliveira TL, Bacelo KL, Forster KM, Ilha V, Rodrigues OE, Hartwig DD. DNA nanovaccines prepared using LemA antigen protect Golden Syrian hamsters against Leptospira lethal infection. Memorias Do Instituto Oswaldo Cruz 2020; 115(2): 1-6.

[28] Teixeira AF, Cavenague MF, Kochi LT, Fernandes LG, Souza GO, Francisco A, et al. Immunoprotective activity induced by leptospiral outer membrane proteins in hamster model of acute leptospirosis. Front Immunol 2020; 11: 568694.

[29] Lauretti-Ferreira F, Silva PLD, Alcântara NM, Silva BF, Grabher I, Souza GO, et al. New strategies for Leptospira vaccine development based on LPS removal. PLoS One 2020; 15(3): 1-16.

[30] Schuler EJA, Marconi RT. The leptospiral general secretory protein D (GspD), a secretin, elicits complement-independent bactericidal antibody against diverse Leptospira species and serovars. Vaccine X 2021; 7: 100089.

[31] Wunder EA, Adhikarla H, Hamond C, Bonner KAO, Liang L, Rodrigues CB, et al. A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus. ELife 2021; 10: 1-20.

[32] Chaurasia R, Salovey A, Guo X, Desir G, Vinetz JM. Vaccination with Leptospira interrogans PF07598 gene family- Encoded virulence modifying proteins protects mice from severe leptospirosis and reduces bacterial load in the liver and kidney. Front Cell Infect Microbiol 2022; 12: 1-14.

[33] Bettin EB, Dorneles J, Hecktheuer AS, Madruga AB, Seixas ACP, Alan N, et al. TonB-dependent receptor epitopes expressed in Mbovis BCG induced significant protection in the hamster model of leptospirosis. . Appl Microbiol Biotechnol 2022; 106(1): 173-184.

[34] Martins G, Guadelupe B, Aym L, Felipe M, Balaro A, et al. The efficacy of vaccination in the prevention of renal and genital leptospirosis in experimentally infected sheep. Trop Med Infect Dis 2022; 7(10): 321.

[35] Elsahn Z, Callagher L, Husted K, Korber S, Siedlok F. Are rigor and transparency enough? Review and future directions for case studies in technology and innovation management. R & D Manage 2020; 50(3): 309-328.

[36] Foxman B. Determining the reliability and validity and interpretation of a measure in the study populations. In: Molecular tools and infectious disease epidemiology. Elsevier: Academic Press; 2011, p. 117-132.

[37] Garba B, Bahaman AB, Khairani-Bejo S, Zakaria Z, Mutalib AR. Retrospective study of leptospirosis in Malaysia. EcoHealth 2017; 14: 389-398.

[38] Sabin NS, Calliope AS, Simpson SV, Arima H, Ito H, Nishimura T, et al. Implications of human activities for (re)emerging infectious diseases, including COVID-19. J Physiol Anthropol 2020; 39(1): 29.

[39] Abd Rahman AN, Hasnul Hadi NH, Sun Z, Thilakavathy K, Joseph N. Regional prevalence of intermediate Leptospira spp. in humans: A meta-analysis. Pathogens 2021; 10(8): 943.

[40] Ghazaei C. Pathogenic Leptospira: Advances in understanding the molecular pathogenesis and virulence. Open Vet J 2018; 8(1): 13-24.

[41] Lata KS, Kumar S, Vaghasia V, Sharma P, Bhairappanvar SB, Soni S, et al. Exploring leptospiral proteomes to identify potential candidates for vaccine design against leptospirosis using an immunoinformatics approach. Sci Rep 2018; 8(1): 6935.

[42] Shkair L, Garanina EE, Stott RJ, Foster TL, Rizvanov AA, Khaiboullina SF. Membrane microvesicles as potential vaccine candidates. Int J Mol Sci 2021; 22(3): 1142.

[43] Barazzone GC, Teixeira AF, Azevedo BO, Damiano DK, Oliveira MP, Nascimento AL, et al. Revisiting the development of vaccines against pathogenic Leptospira: Innovative approaches, present challenges, and future perspectives. Front Immunol 2022; 12: 760291.

[44] Bashiru G, Rani Bahaman A. Advance & challenges in leptospiral vaccine development. Indian J Med Res 2018; 147(1): 15-22.

[45] Zanotto C, Paonlini F, Radelli A, De Giuli Morghen C. Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine. Virol J 2021; 18(1): 50.

[46] Zhang C, Li Z, Xu Y, Zhang Y, Li S, Zhang J, et al. Genetic diversity of Leptospira interrogans circulating isolates and vaccine strains in China from 1954-2014. Hum Vaccin Immunother 2019; 15(2): 381-387.

[47] Giacani L, Molini BJ, Kim EY, Godornes BC, Leader BT, Tantalo LC, et al. Antigenic variation in Treponema pallidum: TprK sequence diversity accumulates in response to immune pressure during experimental syphilis. J Immunol (Baltimore, Md.: 1950) 2010; 184(7): 3822.

[48] Kung F, Anguita J, Pal U. Borrelia burgdorferi and tick proteins supporting pathogen persistence in the vector. Future Microbiol 2012; 8: 41.

[49] Oscherwitz J. The promise and challenge of epitope-focused vaccines. Hum Vaccin Immunother 2016; 12(8): 2113-2116.

[50] Li Q, Chi H, Shi X, Gan Q, Dalmo RA, Tang X, et al. Vaccine adjuvants induce formation of intraperitoneal extracellular traps in Flounder (Paralichthys olivaceus). Front Cell Infect Microbiol 2020; 12: 875409.

[51] Carpenter A, Waltenburg MA, Hall A, Kile J, Killerby M, Knust B, et al. Vaccine preventable zoonotic diseases: Challenges and opportunities for public health progress. Vaccines (Basel) 2022; 10(7): 993.

[52] Klaasen HLBM, Veen MV, Dorrestein-Spierenburg CM, Cao Q. An assessment and comparison of the efficacy of two licensed tetravalent Leptospira vaccines for dogs using an improved challenge model. Vaccines (Basel) 2022; 10(9): 1472.

[53] Mughini-Gras L, Bonfanti L, Natale A, Comin A, Ferronato A, La Greca E, et al. Application of an integrated outbreak management plan for the control of leptospirosis in dairy cattle herds. Epidemiol Infect 2014; 142(6): 1172-1181.

[54] Kashyap D, Panda M, Baral B, Varshney NRS, Bhandari V, Parmar HS, et al. Outer membrane vesicles: An emerging vaccine platform. Vaccines (Basel) 2022; 10(10): 1578.

[55] O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr 2016; 4(1): 10.

[56] Awanye AM, Chang C, Wheeler JX, Chan H, Marsay L, Dold C, et al. Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis. Sci Rep 2019; 9(1): 1-14.

[57] Bugybayeva D, Kydyrbayev Z, Zinina N. A new candidate vaccine for human brucellosis based on influenza viral vectors: A preliminary investigation for the development of an immunization schedule in a guinea pig model. Infect Dis Poverty 2021; 10: 13.

[58] Budihal SM, Perwez K. Leptospirosis diagnosis: Competancy of various laborary tests. J Clin Diagn Res 2014; 8(1): 199-202.

[59] Chugh V, Krishna KV, Pandit A. Cell membrane-coated mimic: Amethodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation. ACS Nano 2021; 15(11): 17080-17123.

[60] Hartwig DD, Forster KM, Oliveira TL, Amaral M, McBride AJ, Dellagostin OA. A prime-boost strategy using the novel vaccine candidate, LemA, protects hamsters against leptospirosis. Clin Vaccine Immunol 2013; 20(5): 747-752.

[61] Vadala M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon? EPMA J 2017; 8(3): 295-311.

[62] De Oliveira NR, Santos FDS, dos Santos VAC, Maia MAC, Oliveira TL, Dellagostin OA. Challenges and strategies for developing recombinant vaccine against leptospirosis: Role of expression platforms and adjuvants in achieving protective efficacy. Pathogens 2023; 12(6): 787.

[63] Shi J, Zhang J, Li S, Sun J, Teng Y, Wu M, et al. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: An in silico approach applied to emerging infectious diseases. PLoS One 2015; 10(12): e0144475.

[64] Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: Current progress and future challenges. Chem Rev 2020; 120(6): 3210-3229.

[65] Sajid A, Singh Y, Shukla P. Computational tools for modern vaccine development. Hum Vaccin Immunother 2020; 16(3): 723-735.

[66] Ravikumar R, Chan J, Prabakaran M. Vaccines against major poultry viral diseases: Strategies to improve the breadth and protective efficacy. Viruses 2022; 14(6): 1195.

[67] Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. COVID-19 vaccines: Rapid development, implications, challenges and future prospects. Hum Cell 2021; 34(3): 711-733.

[68] Lawler JJ, Spencer B, Olden JD, Kim SH, Lowe C, Bolton S, et al. Mitigation and adaptation strategies to reduce climate vulnerabilities and maintain ecosystem services. In: Climate Vulnerability. Elsevier Inc., Academic Press; 2013, p. 315-335.

[69] Lu DP, Jia J, Wei SF, Zhang WL, Liang R, Liu T, et al. Treponema pallidum (Syphilis) antigen TpF1 induces activation of macrophages and accelerates P2X7R-induced NLRP3-dependent release of IL-1β. Endocr Metab Immune Disord Drug Targets 2022; 22(4): 425-432.

[70] Li S, Li W, Jin Y, Wu B, Wu Y. Advancements in the development of nucleic acid vaccines for syphilis prevention and control. Hum Vaccin Immunother 2023; 19(2): 2234790.

[71] Caine JA, Lin YP, Kessler JR, Sato H, Leong JM, Coburn J. Borrelia burgdorferi outer surface protein C (OspC) binds complement component C4b and confers bloodstream survival. Cell Microbiol 2017; 19(12): 10.1111/cmi.12786. doi: 10.1111/cmi.12786. Epub 2017 Sep 26.

[72] Mohseni M, Ameri H, Arab-Zozani M. Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview. Front Med (Lausanne) 2022; 9: 966632.